Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GRAL NASDAQ:PODD NASDAQ:TMDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRALGRAIL$32.96-0.4%$40.79$12.33▼$63.99$1.19B3.26989,259 shs697,589 shsPODDInsulet$303.55+9.5%$299.47$173.00▼$329.33$19.51B1.35553,722 shs1.79 million shsTMDXTransMedics Group$116.05-2.3%$124.11$55.00▼$177.37$4.05B2.091.39 million shs869,973 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRALGRAIL-0.36%-3.65%-23.06%-6.36%+87.06%PODDInsulet+9.47%+5.25%+2.37%-2.21%+59.44%TMDXTransMedics Group-2.31%-2.45%-6.96%+4.08%-20.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGRALGRAIL1.1765 of 5 stars1.14.00.00.02.30.81.3PODDInsulet4.2325 of 5 stars2.44.00.04.92.90.81.9TMDXTransMedics Group2.6411 of 5 stars2.42.00.00.03.22.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGRALGRAIL 2.25Hold$31.50-4.43% DownsidePODDInsulet 2.84Moderate Buy$321.005.75% UpsideTMDXTransMedics Group 2.78Moderate Buy$123.005.99% UpsideCurrent Analyst Ratings BreakdownLatest GRAL, TMDX, and PODD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/7/2025PODDInsuletMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight8/7/2025PODDInsuletJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy8/1/2025TMDXTransMedics GroupMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$115.00 ➝ $123.007/15/2025TMDXTransMedics GroupCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$129.00 ➝ $142.007/8/2025PODDInsuletCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/17/2025TMDXTransMedics GroupOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$130.00 ➝ $150.006/17/2025TMDXTransMedics GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold6/16/2025PODDInsuletTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$365.006/4/2025TMDXTransMedics GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$125.00 ➝ $145.006/3/2025TMDXTransMedics GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/30/2025PODDInsuletThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$380.00(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGRALGRAIL$125.60M9.44$28.66 per share1.15$74.50 per share0.44PODDInsulet$2.07B10.31$4.86 per share62.50$17.27 per share17.58TMDXTransMedics Group$441.54M8.96$1.61 per share72.20$9.33 per share12.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGRALGRAIL-$2.03B-$60.99N/AN/AN/A-1,464.53%-17.99%-15.02%8/12/2025 (Estimated)PODDInsulet$418.30M$5.5654.6061.082.4818.29%22.25%8.29%N/ATMDXTransMedics Group$35.46M$1.9360.1381.15N/A13.49%28.02%8.64%10/27/2025 (Estimated)Latest GRAL, TMDX, and PODD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025GRALGRAIL-$3.14N/AN/AN/A$37.57 millionN/A8/7/2025Q2 2025PODDInsulet$0.92$1.17+$0.25$0.32$612.31 million$649.10 million7/30/2025Q2 2025TMDXTransMedics Group$0.48$0.92+$0.44$0.92$146.64 million$157.37 million5/13/2025Q1 2025GRALGRAIL-$4.03-$3.10+$0.93-$3.10$35.80 million$31.84 million5/8/2025Q1 2025PODDInsulet$0.81$1.02+$0.21$0.50$543.20 million$569.00 million5/8/2025Q1 2025TMDXTransMedics Group$0.29$0.70+$0.41$0.70$123.39 million$143.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGRALGRAILN/AN/AN/AN/AN/APODDInsuletN/AN/AN/AN/AN/ATMDXTransMedics GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGRALGRAILN/A9.709.71PODDInsulet1.214.473.63TMDXTransMedics Group1.619.869.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGRALGRAILN/APODDInsuletN/ATMDXTransMedics Group99.67%Insider OwnershipCompanyInsider OwnershipGRALGRAIL1.85%PODDInsulet0.39%TMDXTransMedics Group7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGRALGRAIL1,36035.97 million35.31 millionOptionablePODDInsulet3,90070.38 million70.10 millionOptionableTMDXTransMedics Group21034.09 million31.70 millionOptionableGRAL, TMDX, and PODD HeadlinesRecent News About These CompaniesTransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by Blair William & Co. ILAugust 7 at 4:15 AM | marketbeat.comWhy TransMedics (TMDX) is a Top Momentum Stock for the Long-TermAugust 6 at 10:51 AM | zacks.comTransMedics Group, Inc. (NASDAQ:TMDX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsAugust 6 at 2:06 AM | americanbankingnews.comTransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Recommendation of "Moderate Buy" from BrokeragesAugust 6 at 2:04 AM | marketbeat.comTransMedics Group (NASDAQ:TMDX) Trading 6.8% Higher Following Analyst UpgradeAugust 6 at 2:13 AM | americanbankingnews.comTransMedics Group (NASDAQ:TMDX) Stock Price Up 6.8% After Analyst UpgradeAugust 5 at 11:10 AM | marketbeat.com5,100 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Acquired by Allianz Asset Management GmbHAugust 5 at 6:17 AM | marketbeat.comTransMedics Group (NASDAQ:TMDX) Upgraded at Wall Street ZenAugust 5 at 2:57 AM | americanbankingnews.comTransMedics stock surges after FDA grants conditional approval for heart trialAugust 4, 2025 | investing.comTransMedics Stock Surges Following FDA Conditional Approval for Heart TrialAugust 4, 2025 | msn.comWhy TransMedics (TMDX) is a Top Growth Stock for the Long-TermAugust 4, 2025 | zacks.comTransMedics Receives FDA IDE Approval to Initiate Next-Generation OCS Heart TrialAugust 4, 2025 | prnewswire.comTransMedics Group (NASDAQ:TMDX) Price Target Raised to $123.00August 4, 2025 | americanbankingnews.comXTX Topco Ltd Acquires Shares of 19,342 TransMedics Group, Inc. (NASDAQ:TMDX)August 3, 2025 | marketbeat.comTransMedics Group (NASDAQ:TMDX) Upgraded by Wall Street Zen to "Buy" RatingAugust 3, 2025 | marketbeat.comTransMedics Group, Inc. (TMDX): A Bull Case TheoryAugust 2, 2025 | insidermonkey.comTransMedics Group, Inc. (TMDX): A Bull Case TheoryAugust 2, 2025 | finance.yahoo.comTransMedics Group (NASDAQ:TMDX) Price Target Raised to $123.00 at Morgan StanleyAugust 2, 2025 | marketbeat.comTransMedics Group (NASDAQ:TMDX) Shares Gap Up After Earnings BeatAugust 2, 2025 | americanbankingnews.comTransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)August 1, 2025 | prnewswire.comTMDX Stock Gains Post Q2 Earnings & Revenue Beat, Margins UpAugust 1, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGRAL, TMDX, and PODD Company DescriptionsGRAIL NASDAQ:GRAL$32.96 -0.12 (-0.36%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$33.00 +0.04 (+0.12%) As of 04:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.Insulet NASDAQ:PODD$303.55 +26.25 (+9.47%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$300.04 -3.51 (-1.16%) As of 04:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.TransMedics Group NASDAQ:TMDX$116.05 -2.75 (-2.31%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$118.54 +2.49 (+2.14%) As of 04:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down Realty Income Rallies Post-Earnings Miss—Here’s What Drove It Don't Mix the Signal for Noise in Super Micro Computer's Earnings Microsoft Stock Gains as Analysts Boost Price Targets Joby Deal Gives Blade New Direction, But Stock Lacks Lift Uber Technologies Is Driving Cash Flow: Ride It Higher for Life How DigitalOcean's Focus Is Fueling Explosive Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
